Logo image of FRX.CA

FENNEC PHARMACEUTICALS INC (FRX.CA) Stock Fundamental Analysis

TSX:FRX - Toronto Stock Exchange - CA31447P1009 - Common Stock - Currency: CAD

11.4  +0.4 (+3.64%)

Fundamental Rating

3

Overall FRX gets a fundamental rating of 3 out of 10. We evaluated FRX against 24 industry peers in the Biotechnology industry. The financial health of FRX is average, but there are quite some concerns on its profitability. FRX has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

FRX had negative earnings in the past year.
In the past year FRX has reported a negative cash flow from operations.
In the past 5 years FRX always reported negative net income.
FRX had negative operating cash flow in 4 of the past 5 years.
FRX.CA Yearly Net Income VS EBIT VS OCF VS FCFFRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

1.2 Ratios

FRX's Return On Assets of -31.41% is fine compared to the rest of the industry. FRX outperforms 70.83% of its industry peers.
Industry RankSector Rank
ROA -31.41%
ROE N/A
ROIC N/A
ROA(3y)-49.42%
ROA(5y)-56.66%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FRX.CA Yearly ROA, ROE, ROICFRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800

1.3 Margins

Looking at the Gross Margin, with a value of 90.27%, FRX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
FRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FRX.CA Yearly Profit, Operating, Gross MarginsFRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, FRX has more shares outstanding
Compared to 5 years ago, FRX has more shares outstanding
Compared to 1 year ago, FRX has an improved debt to assets ratio.
FRX.CA Yearly Shares OutstandingFRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FRX.CA Yearly Total Debt VS Total AssetsFRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

FRX has an Altman-Z score of -3.37. This is a bad value and indicates that FRX is not financially healthy and even has some risk of bankruptcy.
FRX has a Altman-Z score of -3.37. This is in the better half of the industry: FRX outperforms 70.83% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.37
ROIC/WACCN/A
WACCN/A
FRX.CA Yearly LT Debt VS Equity VS FCFFRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 5.14 indicates that FRX has no problem at all paying its short term obligations.
The Current ratio of FRX (5.14) is better than 79.17% of its industry peers.
A Quick Ratio of 4.97 indicates that FRX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 4.97, FRX is doing good in the industry, outperforming 79.17% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.14
Quick Ratio 4.97
FRX.CA Yearly Current Assets VS Current LiabilitesFRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for FRX have decreased strongly by -666.67% in the last year.
Looking at the last year, FRX shows a very negative growth in Revenue. The Revenue has decreased by -31.25% in the last year.
EPS 1Y (TTM)-666.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.51%
Revenue 1Y (TTM)-31.25%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-65.52%

3.2 Future

Based on estimates for the next years, FRX will show a very strong growth in Earnings Per Share. The EPS will grow by 229863.00% on average per year.
The Revenue is expected to grow by 24.62% on average over the next years. This is a very strong growth
EPS Next Y308694732858483400%
EPS Next 2Y12319695932.05%
EPS Next 3Y30116900%
EPS Next 5Y229863%
Revenue Next Year-16.58%
Revenue Next 2Y13.77%
Revenue Next 3Y18.22%
Revenue Next 5Y24.62%

3.3 Evolution

FRX.CA Yearly Revenue VS EstimatesFRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
FRX.CA Yearly EPS VS EstimatesFRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

FRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 9.85, the valuation of FRX can be described as reasonable.
FRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. FRX is cheaper than 95.83% of the companies in the same industry.
FRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.04, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 9.85
FRX.CA Price Earnings VS Forward Price EarningsFRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FRX.CA Per share dataFRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FRX's earnings are expected to grow with 30116900.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12319695932.05%
EPS Next 3Y30116900%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FENNEC PHARMACEUTICALS INC

TSX:FRX (8/8/2025, 7:00:00 PM)

11.4

+0.4 (+3.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners56.63%
Inst Owner ChangeN/A
Ins Owners1.93%
Ins Owner ChangeN/A
Market Cap314.87M
Analysts85.45
Price Target17.28 (51.58%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-39.8%
Min EPS beat(2)-135.44%
Max EPS beat(2)55.84%
EPS beat(4)1
Avg EPS beat(4)-186.92%
Min EPS beat(4)-539.32%
Max EPS beat(4)55.84%
EPS beat(8)3
Avg EPS beat(8)-132.59%
EPS beat(12)4
Avg EPS beat(12)-97.34%
EPS beat(16)7
Avg EPS beat(16)-78.76%
Revenue beat(2)1
Avg Revenue beat(2)-24.33%
Min Revenue beat(2)-53.52%
Max Revenue beat(2)4.87%
Revenue beat(4)1
Avg Revenue beat(4)-27.02%
Min Revenue beat(4)-53.52%
Max Revenue beat(4)4.87%
Revenue beat(8)4
Avg Revenue beat(8)-8.17%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.43%
PT rev (3m)-13.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)46.43%
EPS NY rev (1m)0%
EPS NY rev (3m)152.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.74%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.85
P/S 7.41
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)1.16
Fwd EY10.15%
FCF(TTM)-0.81
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS1.54
BVpS-0.3
TBVpS-0.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.41%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.27%
FCFM N/A
ROA(3y)-49.42%
ROA(5y)-56.66%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.14
Quick Ratio 4.97
Altman-Z -3.37
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-666.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.51%
EPS Next Y308694732858483400%
EPS Next 2Y12319695932.05%
EPS Next 3Y30116900%
EPS Next 5Y229863%
Revenue 1Y (TTM)-31.25%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-65.52%
Revenue Next Year-16.58%
Revenue Next 2Y13.77%
Revenue Next 3Y18.22%
Revenue Next 5Y24.62%
EBIT growth 1Y-284.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2876.34%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.46%
OCF growth 3YN/A
OCF growth 5YN/A